Accelerated dealmaking hits $66 billion as big pharma players look to mitigate steep patent cliff losses and diversify pipelines.

Drug developers relocate clinical trials amid Trump’s NIH research and funding cuts: The final damage to research pipelines is still to be determined, but biotech and pharma companies are already reacting, and more may consider doing so given the uncertainty.